Related Experiment Videos
Early prednisone treatment in Duchenne muscular dystrophy
Luciano Merlini1, Alessandro Cicognani, Elisabetta Malaspina
1Neuromuscular Unit, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy. merlini@ior.it
Insights
Early low-dose prednisone treatment in Duchenne muscular dystrophy (DMD) patients helps maintain muscle function. Steroids prolong ability but do not restore lost function, suggesting early intervention is key.
Area of Science:
- Neurology
- Pediatrics
- Pharmacology
Background:
- Duchenne muscular dystrophy (DMD) is a progressive genetic disorder.
- Current treatments aim to manage symptoms and slow disease progression.
- The optimal timing for initiating corticosteroid therapy in DMD remains under investigation.
Purpose of the Study:
- To evaluate the long-term efficacy of early, alternate-day, low-dose prednisone in young DMD patients.
- To assess the impact of early prednisone on muscle function and strength.
- To identify potential side effects associated with this treatment regimen.
Main Methods:
- Long-term, open-label, parallel-group study with double consent.
- Inclusion of 2-4-year-old patients diagnosed with Duchenne muscular dystrophy.
- Treatment with alternate-day, low-dose prednisone versus a control group.
- Evaluation of muscle function using timed tests and muscle strength via hand-held myometry.
Main Results:
- After 55 months, prednisone-treated patients retained the ability to rise from the floor, unlike some controls.
- Prednisone treatment was associated with prolonged muscle function.
- Observed side effects included decreased growth rate and weight gain in some patients.
Conclusions:
- Early initiation of low-dose prednisone in DMD patients can beneficially prolong muscle function.
- Corticosteroids are effective in preserving existing function but cannot restore lost function.
- Treatment with low-dose prednisone should commence as soon as a definitive DMD diagnosis is established.
Abstract:
The purpose of this long-term, open parallel-group, double-consent study of alternate-day, low-dose prednisone in 2-4-year-old patients with Duchenne muscular dystrophy (DMD) was to determine whether prednisone produces a beneficial effect when given earlier than usual. Muscle function was evaluated by timed tests, and muscle strength with a hand-held myometer. After 55 months of treatment, the five patients (mean age 8.3 years) in the prednisone group were still able to get up from the floor, whereas two of the three in the control group had lost this ability. Side effects included a decline in growth rate in the prednisone-treated patients and excessive weight gain in one control and three treated patients. Because steroids are effective in prolonging function, but not in recovering lost function, we propose that treatment be started with low-dose prednisone in DMD patients as soon as the diagnosis is definite.